Get the Stockscreener App
1.19
1.76%
0.055
Compass Therapeutics Inc stock is traded at $1.19, with a volume of 560.08K.
It is up +1.76% in the last 24 hours and down -54.35% over the past month.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
See More
Previous Close:
$1.135
Open:
$1.17
24h Volume:
560.08K
Relative Volume:
0.17
Market Cap:
$213.40M
Revenue:
$850.00K
Net Income/Loss:
$-68.17M
P/E Ratio:
-2.8912
EPS:
-0.4116
Net Cash Flow:
$-53.29M
1W Performance:
-39.21%
1M Performance:
-54.35%
6M Performance:
-78.96%
1Y Performance:
-66.91%
1-Day Range:
$1.15
$1.195
1-Week Range:
$1.10
$1.88
52-Week Range:
$1.10
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
1.185 | 204.40M | 850.00K | -68.17M | -53.29M | -0.4116 |
VRTX
Vertex Pharmaceuticals Inc
|
521.26 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.50 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.78 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
960.03 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.36 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-26 | Initiated | Craig Hallum | Buy |
| Jan-05-26 | Initiated | William Blair | Outperform |
| Dec-03-25 | Initiated | Canaccord Genuity | Buy |
| Dec-03-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Apr-02-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
How Does FDA Feedback Change the Tovecimig Path for Compass Therapeutics (NASDAQ:CMPX)? - Kalkine Media
Compass Therapeutics Is Maintained at Market Outperform by Citizens - Moomoo
Compass Therapeutics Shares Drop After Downgrade From Wedbush - marketscreener.com
Compass Therapeutics stock downgraded at Wedbush (CMPX:NASDAQ) - Seeking Alpha
Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity (NASDAQ:CMPX) - Seeking Alpha
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’ - Stocktwits
This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Citizens maintains Market Outperform rating on Compass Therapeutics, $4 price target - TradingView
Guggenheim maintains Buy rating on Compass Therapeutics, $4 price target - TradingView
Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 - marketscreener.com
Wedbush downgrades Compass Therapeutics to Neutral, sets price target to $1 - TradingView
Cantor Fitzgerald reiterates Compass Therapeutics stock rating By Investing.com - Investing.com Canada
H.C. Wainwright cuts Compass Therapeutics stock price target on FDA trial recommendation - Investing.com Canada
Guggenheim cuts Compass Therapeutics stock price target on FDA trial requirement - Investing.com Canada
HC Wainwright & Co. maintains Buy rating on Compass Therapeutics, $12 price target - TradingView
Citizens cuts Compass Therapeutics stock price target on FDA trial request - Investing.com Canada
COMPASS THERAPEUTICS INC. : WEDBUSH CUTS TO NEUTRAL FROM OUTPERFORM; CUTS TARGET PRICE TO $1 FROM $5 - Bitget
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside - Stocktwits
Wedbush downgrades Compass Therapeutics stock rating on FDA trial concerns - Investing.com Canada
Why Did Compass Therapeutics Stock Plunge Today?Compass Therapeutics (NASDAQ:CMPX) - Benzinga
Compass shares fall after FDA tovecimig feedback - grafa.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback - Investing News Network
Compass Therapeutics stock price target maintained at $6 by Stifel - Investing.com Canada
Compass Therapeutics Faces FDA Pushback on Tovecimig Trial - TipRanks
Compass Therapeutics Says FDA Recommends New Tovecimig Trial in Biliary Tract Cancer; Shares Fall - marketscreener.com
Form 8K Compass Therapeutics, Inc. For: 22 September By Investing.com - Investing.com Nigeria
CMPX Stock Slides As Traders Watch Volatile Support Zone - StocksToTrade
Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback - TradingView
Compass Therapeutics drops as FDA seeks additional trial for lead asset - TradingView
Compass Therapeutics says FDA recommends survival trial before BLA for tovecimig in biliary tract cancer - TradingView
Compass Therapeutics, Inc. Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback - marketscreener.com
Compass Therapeutics’ CMPX Is Still Waiting On Its BLA Moment - Finimize
CCORF Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compass (CMPX) Earnings Update: The EPS Result Is Below Expectation in the Current Update; After Earnings: Shares Finish 0.21% Higher on the DayProfit Cycle Analysis - vinanet.vn
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
Compass (CMPX) Session: Finishes 4.23% Lower at $2.38; Technical Setup: the Supplied Trading Band Runs From $2.26 to $2.50 in the Current UpdateDollar Neutral Pair - vinanet.vn
NEXTBio Capital Management LP's Compass Therapeutics Inc(CMPX) Holding History - GuruFocus
Compass (CMPX) Earnings Data Review: The EPS Result Is Below Expectation in the Available Record; Investor Response: Shares Close 3.46% Higher in the Latest SessionCore Business Growth - vinanet.vn
Compass Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - simplywall.st
We're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Rate - Moomoo
Compass Therapeutics (CMPX) Climbs 3.26% to $2.22, Approaches Key ResistanceCovered Call Trade - vinanet.vn
HC Wainwright Issues Pessimistic Estimate for CMPX Earnings - MarketBeat
Compass Therapeutics Inc. (CMPX) Stock News Today - TradingKey
Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
A Quick Look at Today's Ratings for Compass Therapeutics(CMPX.US), With a Forecast Between $6 to $7 - Moomoo
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):